Paid reports · powered by Responder Atlas

Responder Full Reports.

Two reports on one compound. The Screen asks which indications respond, and which cell-line subgroups inside them. The Profile takes one indication and goes as deep as the data honestly allows. Both are hypothesis-generating triage on public cell-line data — leads to test, not validated predictions.

Breadth

Responder Screen

One compound, all 17 indications.

Where does this compound do anything, and where is it merely least-inactive? Every indication carries both an absolute effect and a selectivity figure, because either one alone misleads. Response zones name the cell-line subgroups that concentrate the signal, each with its strength tier and its provenance.

All 17 indications, ranked, with absolute and relative effect side by side
Response zones: which cell-line subgroups respond, with tier and provenance
Measured-vs-imputed basis stated for the compound
A zero result is reported as a zero result, not padded

See a sample Responder Screen on vemurafenib

PDF, 5 pages, opens in a new tab. A real report on vemurafenib — an example of the format, not your compound.

Depth

Responder Profile

One compound, one indication you choose.

Everything the Screen says about one indication, plus the layers that only make sense once the indication is fixed: node-level responder subgroups within that tissue, the molecular features that separate responders from non-responders, an independent dependency check, and a named combination partner analysed against the query.

Node-level responder subgroups within your chosen indication
Candidate expression and mutation biomarkers — leads to test, not validated markers
CRISPR dependency characterization, held separate from the response hypothesis
Named combination-partner analysis under a non-interaction null

See a sample Responder Profile on vemurafenib

PDF, 14 pages, opens in a new tab. A real report on vemurafenib — an example of the format, not your compound.

What these are, and are not

Triage on cell lines. Not a clinical prediction.

Both reports run on DepMap/PRISM single-dose viability data. That substrate conflates cytotoxic and cytostatic effects, and a cell-line subgroup is not a patient population. Every biomarker is a candidate to test, never a validated marker.

Where a result is weak, underpowered, or absent, the report says so in those words rather than presenting the strongest available framing. Sections that cannot be computed at adequate power are reported as not computed, with the reason.

Both are scoped per engagement.

Tell us the compound, and the indication if you already know it, and we will tell you what the data can and cannot support before anything is commissioned.

Start free with Indication Lite, or read how the method works on Science.